Hookipa Pharma Sells HBV and HIV Assets to Gilead

Reuters
2025.10.31 12:00
portai
I'm PortAI, I can summarize articles.

HOOKIPA Pharma Inc. has completed the sale of its HB-400 and certain HB-500 program assets to Gilead Sciences, Inc. This transaction involves assets related to the clinical development of treatments for hepatitis B and HIV.

HOOKIPA Pharma Inc. announced the completion of the sale of its assets related to the HB-400 program and certain assets of the HB-500 program to Gilead Sciences, Inc. The transaction includes assets involved in clinical development for hepatitis B and human immunodeficiency virus. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hookipa Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565809-en) on October 31, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer